On 7 October 2026, DEEP SOURCE (00990.HK) said its Penang data centre project secured a 10-year colocation agreement for 67MW and a US$221.1m construction LOI.
On 6 Oct 2026, KINETIC DEV (01277.HK) said its Sierra Leone rutile project began production on 1 Oct, with phase-1 output capacity of 220,000 tonnes.
On 28 September 2026, REGENT PACIFIC (00575.HK) said its unit Deep Longevity will launch Accrua, a consumer digital health platform, in the US in October 2026.
Hansoh (03692.HK) said the EU revoked the marketing authorisation for Aumolertinib (Aumseqa®) on 25 September over a procedural issue; a resubmission is planned.
United Lab (3933.HK) said subsidiary United Biotechnology received US$9.0 million from Novo as the second milestone under the UBT251 exclusive licence deal.
On 24 September 2026, TUHU-W (09690.HK) said it will acquire Conti Trade Australia Pty Ltd, which runs the 279-store mycar Tyre & Auto network in Australia.
On 23 Sept 2026, WUHAN YOUJI (02881.HK) said its unit signed a Malaysia plant phase-1 civil works contract up to RM85m (~RMB140m), a discloseable transaction.
On 22 September 2026, EDVANCE INTL (01410.HK) partnered with Singapore's CWG to co-develop AI agent platform RealRelay.ai.
On 21 September 2026, ABBISKO-B (02256.HK) announced that lavengratinib, its FGFR2/3 inhibitor, showed positive interim Phase II results in paediatric achondroplasia, with AHV rising 2.4 cm/year from baseline and a 100% response rate at 27 weeks.
On 21 September 2026, CUTIA-B (02487.HK) announced that CU-40102 (topical finasteride spray) received marketing approval in Macao for androgenetic alopecia, following earlier approvals in the Chinese mainland and Hong Kong.
This week's Going Global Weekly with mainland enterprises' Hong Kong listings and pharma globalisation forming the two main lines. On the financing side, TRANSSION, RED AVENUE NEW MATERIALS, ROBOTECHNIK and Junxin Environmental Protection passed the Hong Kong Stock Exchange listing hearing, CCTECH and SKYCHEM TECHNOLOGY advanced their H-share plans, Nazhen Technology launched its global offering with net fundraising of up to approximately HK$6.296 billion, and FORMS SYNTRON announced a delayed listing with refunds; on the pharma side, GENFLEET-B, LEADS BIOLABS-B and CSPC PHARMA released clinical data at WCLC, IMPACT THERAP-B received a positive opinion from CHMP, and GENSCRIPT BIO reached a wet laboratory services cooperation with the Lilly TuneLab platform.
This week's Going Global Weekly contains 10 items, with pharmaceuticals and manufacturing forming the two main lines. On the pharmaceutical side, LEE'S PHARM obtained an exclusive licence from 1cBio, STAR SPORTS MED obtained EU CE MDR certification for its full product portfolio, and ASCLETIS-B and CLOVER BIO-B advanced their overseas clinical programmes in parallel; on the manufacturing side, FOUNTAIN SET acquired an 81% equity interest in a Vietnamese textile company for US$27.945 million, and ANJOY FOOD plans to contribute US$37.49625 million to establish a joint-venture production subsidiary in Indonesia. In terms of equity and financing, FOSUN PHARMA sold a 6% stake in India's Gland Pharma for approximately US$294 million, reducing its shareholding to approximately 45.76% while maintaining its controlling position.
On 10 September 2026, BOC AVIATION (02588.HK) announced the purchase of 12 A320NEO aircraft from Airbus on 9 September 2026 for long-term lease to Colombia's Avianca, with all deliveries planned for 2029. The transactions constitute a discloseable transaction under Chapter 14 but are exempt as qualified aircraft leasing activities.
On 10 September 2026, STAR SPORTS MED (01609.HK) announced that it has become the first Chinese sports medicine manufacturer to obtain full product line EU CE MDR certification across 15 product categories, while product registrations in the UK, Australia, Brazil, Singapore, Malaysia and Thailand have been approved.
On 9 September 2026, LEE'S PHARM (00950.HK) announced an exclusive license agreement with US-based 1cBio for OC-3, a preclinical-stage next-generation selective PARP1 inhibitor for homologous recombination repair-deficient cancers, covering development, manufacture and commercialization in Greater China and certain Southeast Asian countries. Lee's Pharmaceutical (Hong Kong) will be responsible for GLP safety studies and manufacturing.
On 9 September 2026, Anjoy Foods Group Co., Ltd. (02648.HK) announced that its wholly-owned Hong Kong subsidiary Hong Kong Anjoy Foods proposed to form a path company with Mutual Strategy Limited under 50.5%/49.5% shareholdings to invest in production and trading subsidiaries in Indonesia, with combined cash contributions of at least USD 74.25 million (including USD 37,496,250 from Anjoy) for producing and selling quick-frozen surimi products and other items; the investment does not constitute a connected transaction or major asset restructuring.
